Cyclacel Pharmaceuticals (NASDAQ:BGMS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:BGMS) from a sell rating to a hold rating in a research note released on Wednesday morning.

Cyclacel Pharmaceuticals Stock Up 1.6%

BGMS stock opened at $1.25 on Wednesday. Cyclacel Pharmaceuticals has a one year low of $1.16 and a one year high of $213.60. The stock has a market cap of $2.80 million, a price-to-earnings ratio of -0.02 and a beta of 0.04.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.